Targeting liver stage malaria with metformin.

Area of Science:

• Infectious Diseases
• Drug Discovery
• Parasitology

Background:

• Malaria control efforts are stagnating due to drug resistance and lack of effective vaccines.
• Alternative strategies, including drug repurposing, are crucial for combating malaria.
• The liver stage of Plasmodium infection is a critical, clinically silent phase for parasite replication.

Purpose of the Study:

• To investigate the potential of repurposing the antidiabetic drug metformin as an antimalarial agent.
• To evaluate metformin's efficacy against the liver stage of Plasmodium parasites.
• To assess the combined effect of metformin and conventional antimalarials.

Main Methods:

• Testing metformin's effect on Plasmodium berghei and Plasmodium falciparum liver stages in vitro.
• Administering prophylactic metformin to mice infected with P. berghei.
• Evaluating the combination of metformin with standard antimalarial drugs in a mouse model.

Main Results:

• Metformin treatment inhibited intracellular parasite growth in the liver stage.
• A reduction in infected hepatocytes was observed in mice treated with metformin.
• Combination therapy with metformin and conventional antimalarials reduced parasite burden and disease severity.

Conclusions:

• Metformin demonstrates efficacy in impairing malaria parasite liver stage development.
• Repurposing metformin as a prophylactic agent could be a viable strategy for malaria chemoprevention.
• Combination therapy involving metformin may enhance malaria treatment outcomes.